Efficacy of a novel formulation of metaflumizone plus amitraz for the treatment of sarcoptic mange in dogs.
A novel spot-on formulation containing metaflumizone plus amitraz (ProMeris/ProMeris Duo for Dogs, Fort Dodge Animal Health, Overland Park, KS) was evaluated for efficacy against sarcoptic mange mites in naturally infested dogs. Sixteen dogs were allocated to two equal groups and were housed individually. Eight of the dogs were treated topically with metaflumizone plus amitraz at the proposed minimum dose rate (20mg/kg of each of metaflumizone and amitraz, at a dose volume of 0.133ml/kg) on Days 0 and 28. The other eight were treated with metaflumizone plus amitraz at the proposed minimum dose rate on Days 0, 14, 28 and 42. To enumerate Sarcoptes scabiei mites, skin scrapings were taken on each of Days 2, 14, 28, 42 and 56. Clinical signs of mange and the extent of sarcoptic lesions were evaluated on each dog when scrapings were made. Evaluation of the efficacy of the treatment was based on the absence of mites supported by the absence of clinical signs associated with canine sarcoptic mange. Treatment with metaflumizone plus amitraz at the minimum proposed dose rate at monthly (two treatments) or two-weekly (four treatments) intervals resulted in a rapid reduction of mites and improved clinical signs. The overall cure rates at Day 56, based on zero mite counts and/or resolution of clinical signs were 75% and 83% of dogs for the monthly and two-weekly regimens, respectively.
Fourie
L J
LJ
ClinVet International, P.O. Box 11186, Universitas 9321, South Africa.
Kok
D J
DJ
du Plessis
A
A
Rugg
D
D
D000818:Animals; D000977:Antiparasitic Agents / Q000592:standards / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000469:parasitology; D004285:Dogs; D004338:Drug Combinations; D005260:Female; D008297:Male; D012520:Sarcoptes scabiei / Q000187:drug effects; D012532:Scabies / Q000188:drug therapy / Q000662:veterinary*; D012664:Semicarbazones / Q000592:standards / Q000627:therapeutic use*; D013997:Time Factors; D014052:Toluidines / Q000592:standards / Q000627:therapeutic use*
D000977:Antiparasitic Agents; D004338:Drug Combinations; D012664:Semicarbazones; D014052:Toluidines; C014983:amitraz; C528570:metaflumizone